Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA for up to ten days.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
136
Start Date
2025-12-09
Completion Date
2026-11-19
Last Updated
2026-07-16
Healthy Volunteers
Yes
Conditions
Interventions
VX-581
Suspension for Oral Administration.
Placebo
Suspension for Oral Administration.
D-IVA
Tablet for Oral Administration.
TEZ
Tablet for Oral Administration.
Locations (1)
Altasciences - Kansas City
Overland Park, Kansas, United States